The lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lupus Hub cannot guarantee the accuracy of translated content. The lupus and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lupus Hub is an independent medical education platform, supported through a grant from AstraZeneca. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lupus content recommended for you
Editorial theme | What are the key considerations when managing comorbidities and infections in patients with SLE?
Betty Diamond
Murray Urowitz
Ricard Cervera
Manuel Francisco Ugarte-Gil
James Cheng-Chung WeiAs a part of our editorial theme on suboptimal management of comorbidities and infections in systemic lupus erythematosus (SLE), we are pleased to present a recorded discussion with our Lupus Hub Steering Committee members. The topic of discussion was key considerations in managing comorbidities and infections in patients with SLE and the session was chaired by Ricard Cervera. Other featured members include Betty Diamond, Murray Urowitz, Manuel Francisco Ugarte-Gil, and James Cheng-Chung Wei.
What are the key considerations when managing comorbidities and infections in patients with SLE?
Cervera opens by discussing the recent 2023 updates of EULAR recommendations for the management of SLE, previously featured on the Lupus Hub. The members discussed the feasibility of implementing these recommendations globally. Urowitz highlights the importance of early recognition of subclinical forms of comorbidities, a topic he previously explored in his expert opinion interview, emphasizing the need for early investigation and treatment; Wei emphasizes osteoporosis, postmenopausal syndrome, and psychosocial aspects. The discussions also explored the strategies for mitigating immunosuppression through vaccinations, including COVID-19, herpes zoster, pneumococcal, and respiratory syncytial virus.
